Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30005504HIVENSG00000143799.14protein_codingPARP1NoYes142P09874
TVIS30026671HIVENSG00000143799.14protein_codingPARP1NoYes142P09874
TVIS30026672HIVENSG00000143799.14protein_codingPARP1NoYes142P09874
TVIS20000916HPVENSG00000143799.14protein_codingPARP1NoYes142P09874
TVIS20046556HPVENSG00000143799.14protein_codingPARP1NoYes142P09874
TVIS44012771HTLV-1ENSG00000143799.14protein_codingPARP1NoYes142P09874
TVIS44010815HTLV-1ENSG00000143799.14protein_codingPARP1NoYes142P09874
TVIS44036114HTLV-1ENSG00000143799.14protein_codingPARP1NoYes142P09874
TCGA Plot Options
Drug Information
GenePARP1
DrugBank IDDB09074
Drug NameOlaparib
Target IDBE0001717
UniProt IDP09874
Regulation Typeinhibitor
PubMed IDs25981132; 33114555; 30069770
CitationsVerhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O'Connor MJ, Jonkers J, Verheij M, van den Brekel MW, Vens C: Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015 Sep;116(3):358-65. doi: 10.1016/j.radonc.2015.03.028. Epub 2015 May 13.@@Tavares TS, Hofman J, Lekesova A, Zelazkova J, Wsol V: Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3. Cancers (Basel). 2020 Oct 26;12(11). pii: cancers12113127. doi: 10.3390/cancers12113127.@@Bochum S, Berger S, Martens UM: Olaparib. Recent Results Cancer Res. 2018;211:217-233. doi: 10.1007/978-3-319-91442-8_15.
GroupsApproved
Direct ClassificationPhthalazinones
SMILESFC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1
Pathways
PharmGKB
ChEMBLCHEMBL521686